The Goldman Sachs Group Lowers Silence Therapeutics (NASDAQ:SLN) Price Target to $4.00

Silence Therapeutics (NASDAQ:SLN) had its price target lowered by equities researchers at The Goldman Sachs Group from $6.00 to $4.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “sell” rating on the stock. The Goldman Sachs Group’s target price would indicate a potential downside of 15.43% from the company’s current price.

SLN has been the topic of several other research reports. BMO Capital Markets reissued an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. HC Wainwright reissued a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Wednesday, January 29th. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Finally, Chardan Capital reissued a “buy” rating and set a $55.00 target price on shares of Silence Therapeutics in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

Silence Therapeutics Stock Up 5.6 %

SLN stock opened at $4.73 on Tuesday. Silence Therapeutics has a fifty-two week low of $4.06 and a fifty-two week high of $27.72. The firm’s 50-day simple moving average is $5.49 and its 200 day simple moving average is $11.53. The stock has a market cap of $141.57 million, a PE ratio of -3.01 and a beta of 1.05.

Hedge Funds Weigh In On Silence Therapeutics

Several large investors have recently made changes to their positions in SLN. Redmile Group LLC boosted its holdings in shares of Silence Therapeutics by 26.3% in the fourth quarter. Redmile Group LLC now owns 2,399,317 shares of the company’s stock worth $16,507,000 after buying an additional 500,000 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Silence Therapeutics by 32.8% in the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock worth $19,798,000 after buying an additional 268,250 shares during the period. Nantahala Capital Management LLC boosted its holdings in shares of Silence Therapeutics by 424.8% in the fourth quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company’s stock worth $7,222,000 after buying an additional 849,676 shares during the period. Eventide Asset Management LLC acquired a new position in shares of Silence Therapeutics in the third quarter worth about $11,635,000. Finally, Point72 Asset Management L.P. boosted its holdings in shares of Silence Therapeutics by 35.3% in the fourth quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company’s stock worth $4,356,000 after buying an additional 165,300 shares during the period. Institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.